Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × osimertinib × 90 days × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 37 Lung Neoplasms 14 Neoplasms 3 Carcinoma 3 Non Small Cell Lung Cancer Metastatic 2 Neoplasm Metastasis 2 NSCLC 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Stage II-IIIB Non-small Cell Lung Carcinoma 1 Stage IB-IIIA Non-small Cell Lung Carcinoma 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 NSCLC Patients With Brain Metastasis 1 Multiple Myeloma 1 Meningeal Carcinomatosis 1 Lymphoma 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1 Inhibition, Psychological 1 Hematologic Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Breast Neoplasms 1 Brain Neoplasms 1 Advanced Non Small Cell Lung Cancer 1

Interventions

Cyclophosphamide 5 fludarabine 4 Dexamethasone 4 blinatumomab 3 Lenalidomide 3 pembrolizumab 2 fludarabine phosphate 2 Cytarabine 2 venetoclax 1 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 tagraxofusp 1 relugolix 1 obinutuzumab 1 nilotinib 1 ixazomib 1 isatuximab 1 inavolisib 1 giredestrant 1 enzalutamide 1 daratumumab 1 abemaciclib 1 Vincristine 1 Transplantation 1 Radiotherapy 1 Neoadjuvant Therapy 1 Monatide (IMS 3015) 1 Methotrexate 1 Melphalan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡